The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · cited 1×
“[1] reported evidence that genetic K-Ras alterations beyond the classical ones could have an important role in human cancer.”
Background
Cited by
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Genomic alterations in lung adenocarcinoma
Devarakonda, S., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 404
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
“The induction of a different sensitivity pattern depending on the specific KRASmutation has been studied in the preclinical scenario by generation of NSCLC cell lines overexpressing the three most common amino acid substitutions (G12C, G12V and G12D) leading to the KRAS-mutated proteins [75].”
BackgroundLiu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
“For example, in vitro data from Garassino et al[31] found that specific KRAS mutations were associated with different sensitivities to chemotherapy.”
BackgroundResultThe genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
“Accordingly, distinct KRAS mutations may lead to differential induction of signal transduction cascades and thus to specific drug sensitivity profiles [19].”
BackgroundA RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
“Clin Cancer Res; 20(15) August 1, 2014 Clinical Cancer Research 3926”
InfluentialMohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3816 · Cited by 79
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76
Chida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K., Fushiki, K., Sawada, K., Kumanishi, R., Shirasu, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13870 · Cited by 50
Ricciuti, B., Son, J., Okoro, J. J., Mira, A., Patrucco, E., Eum, Y., Wang, X., Paranal, R., Wang, H., Lin, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2719 · Cited by 42
Ghimessy, Á. K., Gellert, Á., Schlegl, E., Hegedus, B., Raso, E., Barbai, T., Timar, J., Ostoros, G., Megyesfalvi, Z., Gieszer, B., et al. (2019) · Cancers · doi:10.3390/cancers11101514 · Cited by 27
“In the same study, G12D mutation led to resistance to taxol and sensitivity to sorafenib, whereas the G12V mutation sensitized the cells to cisplatin [13].”
Background
Metadata
- Authors
- Garassino, M. C., Marabese, M., Rusconi, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., & Broggini, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 22
- Issue
- 1
- Pages
- 235-237
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2098272135
- Cited by
- 184
- References
- 2
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.